1. Home
  2. REVBW vs REGCP Comparison

REVBW vs REGCP Comparison

Compare REVBW & REGCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVBW
  • REGCP
  • Stock Information
  • Founded
  • REVBW N/A
  • REGCP N/A
  • Country
  • REVBW United States
  • REGCP United States
  • Employees
  • REVBW 9
  • REGCP 497
  • Industry
  • REVBW Biotechnology: Pharmaceutical Preparations
  • REGCP
  • Sector
  • REVBW Health Care
  • REGCP
  • Exchange
  • REVBW Nasdaq
  • REGCP Nasdaq
  • Market Cap
  • REVBW N/A
  • REGCP N/A
  • IPO Year
  • REVBW 2020
  • REGCP N/A
  • Fundamental
  • Price
  • REVBW $0.02
  • REGCP $23.02
  • Analyst Decision
  • REVBW
  • REGCP
  • Analyst Count
  • REVBW 0
  • REGCP 0
  • Target Price
  • REVBW N/A
  • REGCP N/A
  • AVG Volume (30 Days)
  • REVBW N/A
  • REGCP N/A
  • Earning Date
  • REVBW N/A
  • REGCP N/A
  • Dividend Yield
  • REVBW N/A
  • REGCP N/A
  • EPS Growth
  • REVBW N/A
  • REGCP N/A
  • EPS
  • REVBW N/A
  • REGCP N/A
  • Revenue
  • REVBW N/A
  • REGCP N/A
  • Revenue This Year
  • REVBW N/A
  • REGCP N/A
  • Revenue Next Year
  • REVBW N/A
  • REGCP N/A
  • P/E Ratio
  • REVBW N/A
  • REGCP N/A
  • Revenue Growth
  • REVBW N/A
  • REGCP N/A
  • 52 Week Low
  • REVBW N/A
  • REGCP N/A
  • 52 Week High
  • REVBW N/A
  • REGCP N/A
  • Technical
  • Relative Strength Index (RSI)
  • REVBW N/A
  • REGCP 48.19
  • Support Level
  • REVBW N/A
  • REGCP $23.57
  • Resistance Level
  • REVBW N/A
  • REGCP $24.30
  • Average True Range (ATR)
  • REVBW 0.00
  • REGCP 0.36
  • MACD
  • REVBW 0.00
  • REGCP 0.01
  • Stochastic Oscillator
  • REVBW 0.00
  • REGCP 44.24

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

Share on Social Networks: